MedTrace Logo

Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC

NCT00026624 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2021-11-01

No results posted yet for this study

Summary

The purpose of this study is to determine how safe it is to give patients a shot that has a mixture of a vaccine and dendritic cells (DCs), a special kind of immune cell, and how safe it is to give a shot of the vaccine alone.

Current HIV vaccines have not been strong enough to give good immune responses. Research has shown that the immune response to a vaccine delivered by DCs is greater than the response without DC delivery. A5130 is a study that seeks to give good delivery of the vaccine to important immune cells of the body.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

ALVAC(2)120(B,MN)GNP (vCP1452)

DRUG

Keyhole-Limpet Hemocyanin

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Jeffrey Jacobson

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00026624 on ClinicalTrials.gov